Human 4-1bb agonist antibodies and methods of use thereof
AssigneeBoard of Regents, The University of Texas System
InventorsMichael A. CURRAN, Renee CHIN, Marie-Andrée FORGET, Chantale BERNATCHEZ
Life of this patent
Estimating the term…
Abstract
Isolated or recombinant monoclonal antibodies that bind to 4-1BB are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.
Claims45
An isolated monoclonal antibody, wherein the antibody specifically binds to 4-1BB and comprises:
- (a) a first VH CDR is identical to SEQ ID NO:
- 3;
- (b) a second VH CDR is identical to SEQ ID NO:
- 5;
- (c) a third VH CDR is identical to SEQ ID NO:
- 7;
- (d) a first VL CDR is identical to SEQ ID NO:
- 11;
- (e) a second VL CDR is identical to SEQ ID NO:
- 13;
- and
- (f) a third VL CDR is identical to SEQ ID NO:
- 15;
- or
- (a) a first VH CDR is identical to SEQ ID NO:
- 19;
- (b) a second VH CDR is identical to SEQ ID NO:
- 21;
- (c) a third VH CDR is identical to SEQ ID NO:
- 23;
- (d) a first VL CDR is identical to SEQ ID NO:
- 27;
- (e) a second VL CDR is identical to SEQ ID NO:
- 29;
- and
- (f) a third VL CDR is identical to SEQ ID NO:
- 31;
- or
- (a) a first VH CDR is identical to SEQ ID NO:
- 35;
- (b) a second VH CDR is identical to SEQ ID NO:
- 37;
- (c) a third VH CDR is identical to SEQ ID NO:
- 39;
- (d) a first VL CDR is identical to SEQ ID NO:
- 43;
- (e) a second VL CDR is identical to SEQ ID NO:
- 45;
- and
- (f) a third VL CDR is identical to SEQ ID NO:
- 47;
- or
- (a) a first VH CDR is identical to SEQ ID NO:
- 51;
- (b) a second VH CDR is identical to SEQ ID NO:
- 53;
- (c) a third VH CDR is identical to SEQ ID NO:
- 55;
- (d) a first VL CDR is identical to SEQ ID NO:
- 59;
- (e) a second VL CDR is identical to SEQ ID NO:
- 61;
- and
- (f) a third VL CDR is identical to SEQ ID NO:
- 63.
A recombinant polypeptide comprising an antibody VH domain comprising CDRs 1-3 of the VH domain of clone 54 (SEQ ID NOs:
- 3, 5, and 7), CDRs 1-3 of the VH domain of clone 135B (SEQ ID NOs:
- 19, 21, and 23), CDRs 1-3 of the VH domain of clone 138 (SEQ ID NOs:
- 35, 37, and 39), or CDRs 1-3 of the VH domain of clone 49A (SEQ ID NOs:
- 51, 53, and 55).
A recombinant polypeptide comprising an antibody VL domain comprising CDRs 1-3 of the VL domain of 54 (SEQ ID NOs:
- 11, 13, and 15), CDRs 1-3 of the VL domain of 135B (SEQ ID NOs:
- 27, 29, and 31), CDRs 1-3 of the VL domain of 138 (SEQ ID NOs:
- 43, 45, and 47), or CDRs 1-3 of the VL domain of 49A (SEQ ID NOs:
- 59, 61, and 63).
A recombinant polypeptide comprising an antibody VH domain comprising CDRs 1-3 of the VH domain of clone 54 (SEQ ID NOs:
- 3, 5, and 7) and an antibody VL domain comprising CDRs 1-3 of the VL domain of 54 (SEQ ID NOs:
- 11, 13, and 15);
- an antibody VH domain comprising CDRs 1-3 of the VH domain of clone 135B (SEQ ID NOs:
- 19, 21, and 23) and an antibody VL domain comprising CDRs 1-3 of the VL domain of 135B (SEQ ID NOs:
- 27, 29, and 31);
- an antibody VH domain comprising CDRs 1-3 of the VH domain of clone 138 (SEQ ID NOs:
- 35, 37, and 39) and an antibody VL domain comprising CDRs 1-3 of the VL domain of 138 (SEQ ID NOs:
- 43, 45, and 47);
- or an antibody VH domain comprising CDRs 1-3 of the VH domain of clone 49A (SEQ ID NOs:
- 51, 53, and 55) and an antibody VL domain comprising CDRs 1-3 of the VL domain of 49A (SEQ ID NOs:
- 59, 61, and 63).
Dependencies are inferred from the claim text.